The Story Behind the Science.
It began as the brainchild of University of Chicago and Northwestern graduate students who in 2015, won the National Institutes of Health (NIH) Neuro Startup Challenge.
Today, Beyond Barriers Therapeutics (BBT) is a clinical-stage biotechnology company developing BBT-101: the first-of-its-kind, intranasal therapeutic designed to mitigate the damaging secondary effects of mild traumatic brain injuries (mTBI) (also known as concussions) and moderate TBIs.
BBT is proudly affiliated with the University of Miami through a research collaboration with Dr. Michael Hoffer, a leading neurosurgeon and Co-Principal Investigator currently overseeing one of the company’s clinical trials.
With support from the U.S. Department of Defense, NFLPA, and U.S. Special Operations Command, BBT is working to close a long-standing treatment gap with a rapid, field-ready solution.
Our Team.
The BBT leadership team is comprised of leaders in their own fields: scientists, clinicians, strategists, business executives, and investors united in driving innovation in concussion treatment.
BBT Advisory Board.
BBT’s advisory board brings together cross-disciplinary expertise from leaders in military and trauma medicine, FDA regulatory affairs, nasal drug delivery systems, central nervous system (CNS) therapeutic development, and medical device innovation.
